Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 29786074
Sarhan J, et al. (2018) Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death Differ 29786074
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S388-p - IRF3 (mouse)
Modsite: KTVDLHIsNSQPISL SwissProt Entrez-Gene
Orthologous residues
IRF3 (human): S396‑p, IRF3 (mouse): S388‑p, IRF3 (rat): S390‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase B6
Z-VAD-FMK, LPS increase B6
LPS IFNB1 (mouse) increase IFNB1 -/- no change
Z-VAD-FMK, LPS IFNB1 (mouse) increase IFNB1 -/- no change

S345-p - MLKL (mouse)
Modsite: ELSKTQNsIsRtAKS SwissProt Entrez-Gene
Orthologous residues
MLKL (human): S358‑p, MLKL (mouse): S345‑p, MLKL iso2 (mouse): S345‑p, MLKL (rat): S345‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Z-VAD-FMK, LPS increase B6
Z-VAD-FMK, LPS IFNB1 (mouse) increase IFNB1-/- decrease
Z-VAD-FMK, LPS STING (mouse) increase STING -/- decrease

S166-p - RIPK1 (mouse)
Modsite: VASFKTWsKLTKEKD SwissProt Entrez-Gene
Orthologous residues
RIPK1 (human): S166‑p, RIPK1 iso2 (human): S120‑p, RIPK1 (mouse): S166‑p, RIPK1 (rat): S166‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  macrophage-bone marrow
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Z-VAD-FMK, LPS increase
Necrostatin-1 LPS, Z-VAD-FMK inhibit treatment-induced increase